These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 33406959)
1. Efficacy of Goh KK; Wu TH; Chen CH; Lu ML J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959 [TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. Singh SP; Singh V CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588 [TBL] [Abstract][Full Text] [Related]
3. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Tsai G; Lane HY; Yang P; Chong MY; Lange N Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571 [TBL] [Abstract][Full Text] [Related]
4. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Tsai GE; Lin PY Curr Pharm Des; 2010; 16(5):522-37. PubMed ID: 19909229 [TBL] [Abstract][Full Text] [Related]
5. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Javitt DC Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195 [TBL] [Abstract][Full Text] [Related]
6. Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Marchi M; Galli G; Magarini FM; Mattei G; Galeazzi GM Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):483-493. PubMed ID: 33538213 [No Abstract] [Full Text] [Related]
7. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats. Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471 [TBL] [Abstract][Full Text] [Related]
8. D-serine added to clozapine for the treatment of schizophrenia. Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752 [TBL] [Abstract][Full Text] [Related]
9. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Shim SS; Hammonds MD; Kee BS Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997 [TBL] [Abstract][Full Text] [Related]
10. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211 [TBL] [Abstract][Full Text] [Related]
11. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576 [TBL] [Abstract][Full Text] [Related]
12. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807 [TBL] [Abstract][Full Text] [Related]
13. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Iwata Y; Nakajima S; Suzuki T; Keefe RS; Plitman E; Chung JK; Caravaggio F; Mimura M; Graff-Guerrero A; Uchida H Mol Psychiatry; 2015 Oct; 20(10):1151-60. PubMed ID: 26077694 [TBL] [Abstract][Full Text] [Related]
14. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811 [TBL] [Abstract][Full Text] [Related]
15. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Veerman SR; Schulte PF; Smith JD; de Haan L Psychol Med; 2016 Jul; 46(9):1909-21. PubMed ID: 27048954 [TBL] [Abstract][Full Text] [Related]
16. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. Coyle JT Neurotox Res; 2006 Dec; 10(3-4):221-33. PubMed ID: 17197372 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Chang CH; Lin CH; Liu CY; Chen SJ; Lane HY J Psychopharmacol; 2020 May; 34(5):495-505. PubMed ID: 32122256 [TBL] [Abstract][Full Text] [Related]
18. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Bressan RA; Erlandsson K; Stone JM; Mulligan RS; Krystal JH; Ell PJ; Pilowsky LS Biol Psychiatry; 2005 Jul; 58(1):41-6. PubMed ID: 15992521 [TBL] [Abstract][Full Text] [Related]
19. Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant. Lin CH; Chen YM; Lane HY Curr Drug Targets; 2020; 21(6):610-615. PubMed ID: 31660823 [TBL] [Abstract][Full Text] [Related]
20. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Millan MJ Psychopharmacology (Berl); 2005 Apr; 179(1):30-53. PubMed ID: 15761697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]